arrow
T

Tomohisa Yamamoto

Kansai Medical University
H指数:28
被引数:2,627

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical role of intraperitoneal chemotherapy in patients with pancreatic ductal adenocarcinoma concomitant with occult peritoneal dissemination: A multicenter retrospective study

腹腔化疗在伴有隐匿性腹膜播散的胰腺导管腺癌患者中的临床作用:一项多中心回顾性研究

2025-03-040
OAAI
Preoperative carbohydrate antigen 19.9 level predicts lymph node metastasis in resectable adenocarcinoma of the head of the pancreas: a further plea for biological resectability criteria
2024-10-012
OAAI
Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemotherapy: A multicenter retrospective cohort study (PC-CURE-1)
2024-08-161
OA
A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)

改良FOLFIRINOX与吉西他滨联合nab-紫杉醇治疗局部晚期胰腺癌的随机II期研究 (JCOG1407)

2023-03-0135
OAAI
Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Society based on real-world data
CANCER
IF5.1
2022-12-123
PRE
Synopsis of a clinical practice guideline for pancreatic ductal adenocarcinoma with peritoneal dissemination in Japan; Japan Peritoneal Malignancy Study Group
2022-01-0714
OA
A simple risk score for detecting radiological occult metastasis in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma

用于检测可切除或可切除的胰腺导管腺癌患者的放射学隐匿性转移的简单风险评分

2021-08-2419
PREAI
Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113
2021-06-183
OAAI